Pacira BioSciences sells pain treatments such as EXPAREL and ZILRETTA to patients and healthcare providers. PCRX reports earnings on Thu, Nov 5, 2026. Analyst consensus is Hold, based on the latest ratings from 8 firms (2 buy, 6 hold, 0 sell). In the past 30 days there were 5 dark pool prints.
Prices, price targets and earnings estimates for PCRX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PCRX is in one of them and how their past PCRX trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Pacira BioSciences
Pacira BioSciences is a pharmaceutical company based in Brisbane, California. It sells pain treatments that do not rely on opioids. Its main products are EXPAREL, a local pain treatment used around surgery that works over an extended period, ZILRETTA, a knee injection that releases medicine over time for osteoarthritis pain, and the iovera handheld device, which uses cold to block pain signals in targeted nerves. Its customers include patients and the healthcare providers who treat them.
